{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:24:53Z","timestamp":1777695893541,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jncc.2021.08.002","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T09:18:50Z","timestamp":1629623930000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval"],"prefix":"10.1016","volume":"1","author":[{"given":"Huiyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4931-3409","authenticated-orcid":false,"given":"Huilei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-8066","authenticated-orcid":false,"given":"Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jncc.2021.08.002_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jncc.2021.08.002_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jncc.2020.12.001","article-title":"Cancer incidence and mortality in China, 2015","volume":"1","author":"Zhang","year":"2021","journal-title":"Journal of the National Cancer Center"},{"issue":"11","key":"10.1016\/j.jncc.2021.08.002_bib0003","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S1470-2045(19)30491-7","article-title":"Changes in clinical trials of cancer drugs in mainland China over the decade 2009\u201318: a systematic review","volume":"20","author":"Li","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jncc.2021.08.002_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd.2017.94","article-title":"Chinese biopharma starts feeding the global pipeline","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jncc.2021.08.002_bib0005","unstructured":"National Medical Products Administration. China Food and Drug Administration Registration and Information Disclosure Platform for Drug Clinical Studies. Accessed February 17, 2021. http:\/\/www.chinadrugtrials.org.cn\/"},{"key":"10.1016\/j.jncc.2021.08.002_bib0006","unstructured":"Informa Pharma Intelligence. Trialtrove. Accessed February 17, 2021. https:\/\/citeline.informa.com\/"},{"key":"10.1016\/j.jncc.2021.08.002_bib0007","unstructured":"National Medical Products Administration. Drugs. Accessed February 17, 2021. http:\/\/app1.nmpa.gov.cn\/"},{"key":"10.1016\/j.jncc.2021.08.002_bib0008","unstructured":"U.S. Food and Drug Administration. Advancing health through innovation: new drug therapy approvals 2020. Accessed February 17, 2021. https:\/\/www.fda.gov\/drugs"},{"key":"10.1016\/j.jncc.2021.08.002_bib0009","unstructured":"Informa Pharma Intelligence. Trialtrove. Accessed February 17, 2021. https:\/\/citeline.zendesk.com\/hc\/en-us\/articles\/360010048754-Which-sponsors-make-up-the-Industry-Top-20-Pharma-category-under-Sponsor-Type-"},{"key":"10.1016\/j.jncc.2021.08.002_bib0010","unstructured":"U.S. Food and Drug Administration. Expedited Programs for Serious Conditions\u2013\u2013Drugs and Biologics. Accessed May, 2014. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/expedited-programs-serious-conditions-drugs-and-biologics."},{"issue":"6","key":"10.1016\/j.jncc.2021.08.002_bib0011","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China [J]","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.jncc.2021.08.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01055","article-title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) [J]","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jncc.2021.08.002_bib0013","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jncc.2021.08.002_bib0014","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J]","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jncc.2021.08.002_bib0015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/d41573-020-00150-9","article-title":"Clinical trial recovery from COVID-19 disruption","volume":"19","author":"Xue","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.jncc.2021.08.002_bib0016","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/d41573-020-00093-1","article-title":"Impact of COVID-19 on oncology clinical trials","volume":"19","author":"Upadhaya","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.jncc.2021.08.002_bib0017","first-page":"127","article-title":"Progress on clinical trials of cancer drugs in China, 2019","volume":"42","author":"Huang","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.jncc.2021.08.002_bib0018","unstructured":"National Medical Products Administration. Provisions of Drug Registration. no. 27. January 22, 2020 (in Chinese). Accessed July 30, 2021. http:\/\/www.cde.org.cn\/policy.do?method=view&id=aab95e7996170aab."},{"key":"10.1016\/j.jncc.2021.08.002_bib0019","unstructured":"U.S. Food and Drug Administration. A Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Accessed July 30, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics."},{"issue":"6","key":"10.1016\/j.jncc.2021.08.002_bib0020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.drudis.2014.11.005","article-title":"Cancer drug development in China: recent advances and future challenges","volume":"20","author":"Wu","year":"2015","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.jncc.2021.08.002_bib0021","first-page":"327","article-title":"Comparison of current status and perspective of lung cancer clinical studies between China and the United States","volume":"27","author":"Wang","year":"2020","journal-title":"Chinese Journal of Clinical Thoracic and Cardiovascular Surgery"},{"issue":"10","key":"10.1016\/j.jncc.2021.08.002_bib0022","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1200\/JCO.18.02037","article-title":"Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology","volume":"37","author":"Pal","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005421000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667005421000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:36:06Z","timestamp":1763019366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667005421000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2667005421000375"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2021.08.002","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2021.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}